US2021371543A1PendingUtilityA1

Thrombin-Binding Antibody Molecules And Uses Thereof

74
Assignee: JANSSEN PHARMACEUTICALS INCPriority: Dec 14, 2011Filed: Jun 10, 2021Published: Dec 2, 2021
Est. expiryDec 14, 2031(~5.4 yrs left)· nominal 20-yr term from priority
Inventors:James Andrew HuntingtonTrevor BaglinJonathan Langdown
C07K 16/36C07K 2317/34A61P 35/00C07K 16/40C07K 2317/21C07K 2317/55C07K 2317/70A61P 31/00C07K 2317/565A61P 9/10A61P 29/00A61P 43/00A61P 7/02C07K 2317/76A61K 2039/505C07K 2317/92A61P 25/28A61P 35/04A61P 7/04
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A lyophilized antibody molecule comprising a VH domain comprising a HCDR1 having the amino acid sequence of SEQ ID NO: 3, a HCDR2 having the amino acid sequence of SEQ ID NO: 4, and a HCDR3 having the amino acid sequence of SEQ ID NO: 5, a VL domain comprising a LCDR1 having the amino acid sequence of SEQ ID NO: 7, a LCDR2 having the amino acid sequence of SEQ ID NO: 8, and a LCDR3 having the amino acid sequence of SEQ ID NO: 9, and an IgG constant region, wherein the antibody molecule specifically binds to the exosite 1 region of thrombin. 
     
     
         2 . The lyophilized antibody molecule according to  claim 1 , wherein the VL domain has the amino acid sequence of SEQ ID NO: 6. 
     
     
         3 . The lyophilized antibody molecule according to  claim 1 , wherein the VH domain has the amino acid sequence of SEQ ID NO: 2.

Join the waitlist — get patent alerts

Track US2021371543A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.